Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.51 |
| ▸ | XPO1 | O14980 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14686366 | 0.98 | CYP2A6 (0.50) | CYP2A6XPO1LMNATDP1KMT2A | |
| SCHEMBL15842322 | 0.77 | KDM4E (0.44) | CYP2A6XPO1LMNATDP1KMT2A | |
| SCHEMBL30524350 | 0.75 | CYP2A6 (0.58) | CYP2A6XPO1LMNATDP1THRB | |
| SCHEMBL5535389 | 0.74 | CYP2A6 (0.56) | CYP2A6XPO1LMNATDP1THRB | |
| SCHEMBL3287800 | 0.73 | XPO1 (0.68) | CYP2A6XPO1LMNATDP1THRB | |
| Coumarin SCHEMBL28473865 | 0.73 | MCL1 (0.62) | CYP2A6LMNATDP1KMT2ATHRB | |
| Coumarin SCHEMBL28899947 | 0.73 | MCL1 (0.62) | CYP2A6LMNATDP1KMT2ATHRB | |
| 8-Hydroxycoumarin SCHEMBL1366927 | 0.72 | MCL1 (0.62) | CYP2A6XPO1LMNATDP1THRB | |
| SCHEMBL3282340 | 0.72 | CYP2A6 (0.55) | CYP2A6XPO1LMNATDP1THRB | |
| SCHEMBL8684869 | 0.72 | CYP2A6 (0.55) | CYP2A6XPO1LMNATDP1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104237194-B | Fluorescent spectrometry for detecting micro-Mg2+, Zn2+ or F- | 贵州大学 | 2017-01-11 | — | — | CN | claimed |
| US-9127092-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | claimed |
| US-20140187725-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2014-07-03 | — | — | US | claimed |
| CN-104237194-B | Fluorescent spectrometry for detecting micro-Mg2+, Zn2+ or F- | 贵州大学 | 2017-01-11 | — | — | CN | disclosed |
| US-9127092-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | disclosed |
| CN-104277023-A | Preparation method of 8-formyl coumarin derivative | SHANGHAI AIPU PLANT TECHNOLOGY CO LTD | 2015-01-14 | — | — | CN | disclosed |
| CN-104277023-A | Preparation method of 8-formyl coumarin derivative | SHANGHAI AIPU PLANT TECHNOLOGY CO LTD | 2015-01-14 | — | — | CN | disclosed |
| US-20140187725-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2014-07-03 | — | — | US | disclosed |
| US-7994318-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7872142-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709664-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | disclosed |
| US-7026491-B2 | Coumarin derivatives useful as TNFα inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-04-11 | — | — | US | disclosed |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2002008217-A2 | COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014705-A1 | Coumarin derivatives useful as tnf alpha inhibitors | TNF, NFKBIA, TNFRSF1A | CYP2A6 1537/4885XPO1 395/4885LMNA 1762/4885 |
| US-20100197917-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | CYP2A6 1437/4885XPO1 464/4885LMNA 1585/4885 |
| US-20100174076-A1 | COUMARIN DERIVATIVES USEFUL AS TNF ALPHA INHIBITORS | TNF, NFKBIA, TNFRSF1A | CYP2A6 1437/4885XPO1 464/4885LMNA 1585/4885 |
| US-20060020138-A1 | Coumarin derivatives useful as TNFalpha inhibitors | TNF, NFKBIA, TNFRSF1A | CYP2A6 1314/4885XPO1 722/4885LMNA 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.